American Century Companies Inc. Boosts Position in IQVIA Holdings Inc. (NYSE:IQV)

American Century Companies Inc. boosted its stake in IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 396.0% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,134,737 shares of the medical research company's stock after purchasing an additional 905,960 shares during the quarter. American Century Companies Inc. owned about 0.63% of IQVIA worth $222,987,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds have also bought and sold shares of the stock. Private Trust Co. NA boosted its holdings in shares of IQVIA by 10.7% in the 3rd quarter. Private Trust Co. NA now owns 485 shares of the medical research company's stock worth $115,000 after purchasing an additional 47 shares in the last quarter. Pine Valley Investments Ltd Liability Co boosted its stake in IQVIA by 0.5% in the third quarter. Pine Valley Investments Ltd Liability Co now owns 9,481 shares of the medical research company's stock worth $2,247,000 after buying an additional 50 shares in the last quarter. Howard Capital Management Inc. grew its position in IQVIA by 4.9% during the fourth quarter. Howard Capital Management Inc. now owns 1,147 shares of the medical research company's stock valued at $225,000 after acquiring an additional 54 shares during the last quarter. Wealth Enhancement Advisory Services LLC raised its stake in shares of IQVIA by 1.0% during the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 5,434 shares of the medical research company's stock worth $1,068,000 after acquiring an additional 56 shares in the last quarter. Finally, Cypress Wealth Services LLC lifted its holdings in shares of IQVIA by 4.8% in the 4th quarter. Cypress Wealth Services LLC now owns 1,243 shares of the medical research company's stock worth $244,000 after acquiring an additional 57 shares during the last quarter. 89.62% of the stock is currently owned by institutional investors.

Remove Ads

IQVIA Stock Down 2.7 %

IQV traded down $5.04 during trading on Tuesday, hitting $181.07. 1,192,314 shares of the company's stock traded hands, compared to its average volume of 1,239,209. IQVIA Holdings Inc. has a 12-month low of $179.28 and a 12-month high of $254.54. The company's 50 day simple moving average is $194.58 and its two-hundred day simple moving average is $207.73. The company has a current ratio of 0.84, a quick ratio of 0.84 and a debt-to-equity ratio of 2.12. The stock has a market capitalization of $31.93 billion, a price-to-earnings ratio of 24.14, a PEG ratio of 1.99 and a beta of 1.50.

IQVIA (NYSE:IQV - Get Free Report) last released its quarterly earnings data on Thursday, February 6th. The medical research company reported $2.90 EPS for the quarter, missing the consensus estimate of $3.11 by ($0.21). IQVIA had a return on equity of 28.81% and a net margin of 8.91%. Analysts predict that IQVIA Holdings Inc. will post 10.84 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of equities analysts recently commented on IQV shares. Bank of America decreased their target price on shares of IQVIA from $255.00 to $235.00 and set a "buy" rating on the stock in a research report on Friday, December 13th. JPMorgan Chase & Co. lowered their target price on IQVIA from $240.00 to $232.00 and set an "overweight" rating for the company in a research note on Tuesday, February 18th. UBS Group reduced their price target on IQVIA from $260.00 to $255.00 and set a "buy" rating on the stock in a research report on Friday, February 7th. StockNews.com downgraded IQVIA from a "buy" rating to a "hold" rating in a research report on Wednesday, March 12th. Finally, BTIG Research cut shares of IQVIA from a "buy" rating to a "neutral" rating in a report on Monday, February 3rd. Five equities research analysts have rated the stock with a hold rating, sixteen have issued a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $249.05.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.